Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease; CREDO 2

Cobertura de los medios

• Nombre	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease; CREDO 2
  Nombre/canal del medio de comunicación	Clinical Trials.gov
  Fecha	2/10/18
  Personas	Diego Luis Saaibi Solano